CHD4 Targeting Peptide Isolated From Viral Protein For Cancer Therapeutics

Tech ID: 33318 / UC Case 2022-557-0


Researchers at the University of California, Davis have identified a short peptide which rapidly promotes protein degradation in cancerous enzymes and induces cell differentiation to kill lymphomas.

Full Description

Researchers at the University of California Davis have discovered a small peptide from viral protein sequence that has been shown to interact with CHD4, a regulating protein that is deregulated in cancerous cells. Specifically, the presence of the discovered peptide causes the CHD4 protein to degrade faster, ultimately killing the cancer cells. The peptide can bind to CHD4 well, facilitate differentiation of cancer cells, slow cancer cell growth, and trigger programmed cell death. Further, using a lymphoma mouse model, the researchers demonstrated inhibition of cancer cell growth without any measurable toxicity. The peptide has potential use for the regulation of the CHD4 protein and oncology treatments.


  • Induction of cell differentiation 
  • Oncology


  • Therapeutic purposes 
  • Regulation of proteins, specifically CHD4 
  • Weakening cancer cell growth in organisms

Patent Status

Country Type Number Dated Case
Patent Cooperation Treaty Published Application WO 2023/215235 11/09/2023 2022-557

Additional Patent Pending


Learn About UC TechAlerts - Save Searches and receive new technology matches


  • Izumiya, Yoshihiro

Other Information


peptides, cancer cell growth, CHD4, cell differentiation, differentiation therapy, protein regulation, gene expression

Categorized As